Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory <i>ALK</i> ‐positive NSCLC from a phase II studyJing Zheng, Li Zhang, Yunpeng Yang et al.|癌症：英文版|2024Cited by 9